Current Status of Left Ventricular Assist Device Therapy

Pavol Sajgalik, Avishay Grupper, Brooks Sayre Edwards, Sudhir S. Kushwaha, John M. Stulak, David L. Joyce, Lyle D. Joyce, Richard C. Daly, Tomas Kara, John A. Schirger

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

Congestive heart failure (HF) remains a serious burden in the Western World. Despite advances in pharmacotherapy and resynchronization, many patients have progression to end-stage HF. These patients may be candidates for heart transplant or left ventricular assist device (LVAD) therapy. Heart transplants are limited by organ shortages and in some cases by patient comorbidities; therefore, LVAD therapy is emerging as a strategy of bridge to transplant or as a destination therapy in patients ineligible for transplant. Patients initially ineligible for a transplant may, in certain cases, become eligible for transplant after physiologic improvement with LVAD therapy, and a small number of patients with an LVAD may have sufficient recovery of myocardial function to allow device explantation. This clinically oriented review will describe (1) the most frequently used pump types and aspects of the continuous-flow physiology and (2) the clinical indications for and the shift toward the use of LVADs in less sick patients with HF. Additionally, we review complications of LVAD therapy and project future directions in this field. We referred to the Interagency Registry for Mechanically Assisted Circulatory Support, landmark trials, and results from recently published studies as major sources in obtaining recent outcomes, and we searched for related published literature via PubMed. This review focuses primarily on clinical practice for primary care physicians and non-HF cardiologists in the United States.

Original languageEnglish (US)
Pages (from-to)927-940
Number of pages14
JournalMayo Clinic Proceedings
Volume91
Issue number7
DOIs
StatePublished - Jul 1 2016

Fingerprint

Heart-Assist Devices
Transplants
Heart Failure
Therapeutics
Western World
Recovery of Function
Primary Care Physicians
PubMed
Registries
Comorbidity
Drug Therapy
Equipment and Supplies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sajgalik, P., Grupper, A., Edwards, B. S., Kushwaha, S. S., Stulak, J. M., Joyce, D. L., ... Schirger, J. A. (2016). Current Status of Left Ventricular Assist Device Therapy. Mayo Clinic Proceedings, 91(7), 927-940. https://doi.org/10.1016/j.mayocp.2016.05.002

Current Status of Left Ventricular Assist Device Therapy. / Sajgalik, Pavol; Grupper, Avishay; Edwards, Brooks Sayre; Kushwaha, Sudhir S.; Stulak, John M.; Joyce, David L.; Joyce, Lyle D.; Daly, Richard C.; Kara, Tomas; Schirger, John A.

In: Mayo Clinic Proceedings, Vol. 91, No. 7, 01.07.2016, p. 927-940.

Research output: Contribution to journalReview article

Sajgalik, P, Grupper, A, Edwards, BS, Kushwaha, SS, Stulak, JM, Joyce, DL, Joyce, LD, Daly, RC, Kara, T & Schirger, JA 2016, 'Current Status of Left Ventricular Assist Device Therapy', Mayo Clinic Proceedings, vol. 91, no. 7, pp. 927-940. https://doi.org/10.1016/j.mayocp.2016.05.002
Sajgalik P, Grupper A, Edwards BS, Kushwaha SS, Stulak JM, Joyce DL et al. Current Status of Left Ventricular Assist Device Therapy. Mayo Clinic Proceedings. 2016 Jul 1;91(7):927-940. https://doi.org/10.1016/j.mayocp.2016.05.002
Sajgalik, Pavol ; Grupper, Avishay ; Edwards, Brooks Sayre ; Kushwaha, Sudhir S. ; Stulak, John M. ; Joyce, David L. ; Joyce, Lyle D. ; Daly, Richard C. ; Kara, Tomas ; Schirger, John A. / Current Status of Left Ventricular Assist Device Therapy. In: Mayo Clinic Proceedings. 2016 ; Vol. 91, No. 7. pp. 927-940.
@article{552d1785e2d447059bf5da26bb5650a8,
title = "Current Status of Left Ventricular Assist Device Therapy",
abstract = "Congestive heart failure (HF) remains a serious burden in the Western World. Despite advances in pharmacotherapy and resynchronization, many patients have progression to end-stage HF. These patients may be candidates for heart transplant or left ventricular assist device (LVAD) therapy. Heart transplants are limited by organ shortages and in some cases by patient comorbidities; therefore, LVAD therapy is emerging as a strategy of bridge to transplant or as a destination therapy in patients ineligible for transplant. Patients initially ineligible for a transplant may, in certain cases, become eligible for transplant after physiologic improvement with LVAD therapy, and a small number of patients with an LVAD may have sufficient recovery of myocardial function to allow device explantation. This clinically oriented review will describe (1) the most frequently used pump types and aspects of the continuous-flow physiology and (2) the clinical indications for and the shift toward the use of LVADs in less sick patients with HF. Additionally, we review complications of LVAD therapy and project future directions in this field. We referred to the Interagency Registry for Mechanically Assisted Circulatory Support, landmark trials, and results from recently published studies as major sources in obtaining recent outcomes, and we searched for related published literature via PubMed. This review focuses primarily on clinical practice for primary care physicians and non-HF cardiologists in the United States.",
author = "Pavol Sajgalik and Avishay Grupper and Edwards, {Brooks Sayre} and Kushwaha, {Sudhir S.} and Stulak, {John M.} and Joyce, {David L.} and Joyce, {Lyle D.} and Daly, {Richard C.} and Tomas Kara and Schirger, {John A.}",
year = "2016",
month = "7",
day = "1",
doi = "10.1016/j.mayocp.2016.05.002",
language = "English (US)",
volume = "91",
pages = "927--940",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "7",

}

TY - JOUR

T1 - Current Status of Left Ventricular Assist Device Therapy

AU - Sajgalik, Pavol

AU - Grupper, Avishay

AU - Edwards, Brooks Sayre

AU - Kushwaha, Sudhir S.

AU - Stulak, John M.

AU - Joyce, David L.

AU - Joyce, Lyle D.

AU - Daly, Richard C.

AU - Kara, Tomas

AU - Schirger, John A.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Congestive heart failure (HF) remains a serious burden in the Western World. Despite advances in pharmacotherapy and resynchronization, many patients have progression to end-stage HF. These patients may be candidates for heart transplant or left ventricular assist device (LVAD) therapy. Heart transplants are limited by organ shortages and in some cases by patient comorbidities; therefore, LVAD therapy is emerging as a strategy of bridge to transplant or as a destination therapy in patients ineligible for transplant. Patients initially ineligible for a transplant may, in certain cases, become eligible for transplant after physiologic improvement with LVAD therapy, and a small number of patients with an LVAD may have sufficient recovery of myocardial function to allow device explantation. This clinically oriented review will describe (1) the most frequently used pump types and aspects of the continuous-flow physiology and (2) the clinical indications for and the shift toward the use of LVADs in less sick patients with HF. Additionally, we review complications of LVAD therapy and project future directions in this field. We referred to the Interagency Registry for Mechanically Assisted Circulatory Support, landmark trials, and results from recently published studies as major sources in obtaining recent outcomes, and we searched for related published literature via PubMed. This review focuses primarily on clinical practice for primary care physicians and non-HF cardiologists in the United States.

AB - Congestive heart failure (HF) remains a serious burden in the Western World. Despite advances in pharmacotherapy and resynchronization, many patients have progression to end-stage HF. These patients may be candidates for heart transplant or left ventricular assist device (LVAD) therapy. Heart transplants are limited by organ shortages and in some cases by patient comorbidities; therefore, LVAD therapy is emerging as a strategy of bridge to transplant or as a destination therapy in patients ineligible for transplant. Patients initially ineligible for a transplant may, in certain cases, become eligible for transplant after physiologic improvement with LVAD therapy, and a small number of patients with an LVAD may have sufficient recovery of myocardial function to allow device explantation. This clinically oriented review will describe (1) the most frequently used pump types and aspects of the continuous-flow physiology and (2) the clinical indications for and the shift toward the use of LVADs in less sick patients with HF. Additionally, we review complications of LVAD therapy and project future directions in this field. We referred to the Interagency Registry for Mechanically Assisted Circulatory Support, landmark trials, and results from recently published studies as major sources in obtaining recent outcomes, and we searched for related published literature via PubMed. This review focuses primarily on clinical practice for primary care physicians and non-HF cardiologists in the United States.

UR - http://www.scopus.com/inward/record.url?scp=84991706726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991706726&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2016.05.002

DO - 10.1016/j.mayocp.2016.05.002

M3 - Review article

VL - 91

SP - 927

EP - 940

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 7

ER -